Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NeuroOne Medical TechnologiesNMTC -3.11%21 3-Year EBITDA Growth Rate is 50.50% as of Jun. 2026. GuruFocus rates NMTC with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 687 Medical Devices & Instruments companies, NeuroOne Medical Technologies ranks better than 88.21% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 50.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 36.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of NeuroOne Medical Technologies was 50.50% per year. The lowest was -337.80% per year. And the median was -6.80% per year.
NeuroOne Medical Technologies (NAS:NMTC) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
NeuroOne Medical Technologies 3-Year EBITDA Growth Rate Related Terms
NMTC vs PMI, HSCS, IRIX: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, NeuroOne Medical Technologies's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeuroOne Medical Technologies 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NeuroOne Medical Technologies's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where NeuroOne Medical Technologies's 3-Year EBITDA Growth Rate falls into.
NeuroOne Medical Technologies 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 50.50% mean?
NeuroOne Medical Technologies (NMTC) has a 3-Year EBITDA Growth Rate of 50.50% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for NeuroOne Medical Technologies and its competitors. According to the industry distribution chart, NeuroOne Medical Technologies ranks #81 out of 687 companies in the Medical Devices & Instruments industry, placing it in the top 11.8%.
Is NeuroOne Medical Technologies' 3-Year EBITDA Growth Rate too high?
NeuroOne Medical Technologies' current 3-Year EBITDA Growth Rate is 50.50%. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.10. NeuroOne Medical Technologies' value of 50.50% is 523.5% above this industry median. Based on the distribution chart, NeuroOne Medical Technologies ranks #81 out of 687 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, NeuroOne Medical Technologies has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does NeuroOne Medical Technologies' 3-Year EBITDA Growth Rate compare to PMI and HSCS?
According to the Medical Devices & Instruments industry distribution chart, NeuroOne Medical Technologies ranks #81 out of 687 companies for 3-Year EBITDA Growth Rate. This places NeuroOne Medical Technologies in the top 12% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.10. NeuroOne Medical Technologies' value of 50.50% is 523.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NeuroOne Medical Technologies's current 3-Year EBITDA Growth Rate of 50.50% is 523.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for NeuroOne Medical Technologies and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeuroOne Medical Technologies's current 3-Year EBITDA Growth Rate is 50.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroOne Medical Technologies stock overvalued right now?
NeuroOne Medical Technologies (NMTC) has a current 3-Year EBITDA Growth Rate of 50.50%. The current 3-Year EBITDA Growth Rate is 50.50% and 523.5% above the Medical Devices & Instruments industry median of 8.10. NeuroOne Medical Technologies' overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For NeuroOne Medical Technologies (NMTC), the current 3-Year EBITDA Growth Rate is 50.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.
21GF Score
Get the complete analysis for NMTC
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NMTC has been successfully added to your 
